Progress in Rituximab injection for treatment of refractory nephrotic syndrome in children

  • SUN Li ,
  • GAO Xia
Expand
  • 1. Department of Pediatrics, Gansu Provincial Hospital, Lanzhou 730000, Gansu, China; 2. Department of Rheumatology, Children’s Hospital of Fudan University, Shanghai 201102, China

Received date: 2017-04-15

  Online published: 2017-04-15

Abstract

Glucocorticoid is the first choice for the treatment of nephrotic syndrome in children. But due to various reasons, nephrotic syndrome becomes hormone dependent or resistant, and progresses into refractory nephrotic syndrome in some children, which forces the clinician to constantly look for new immunosuppressants in order to alleviate the condition.,Rituximab injection (RTX) as a monoclonal antibody against CD20 has been widely used in the treatment of a variety of immune diseases in recent years. The use of RTX in refractory nephrotic syndrome in children, its main adverse effects and possible mechanisms was reviewed in this article.

Cite this article

SUN Li , GAO Xia . Progress in Rituximab injection for treatment of refractory nephrotic syndrome in children[J]. Journal of Clinical Pediatrics, 2017 , 35(4) : 315 . DOI: 10.3969/j.issn.1000-3606.2017.04.019

Outlines

/